Nanomanipulation coupled nanospray mass spectrometry (NMS)
US-9218947-B2 · Dec 22, 2015 · US
US9443708B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9443708-B2 |
| Application number | US-201414482332-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 10, 2014 |
| Priority date | Sep 10, 2014 |
| Publication date | Sep 13, 2016 |
| Grant date | Sep 13, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A system and process are disclosed for ultrasensitive determination of target isotopes of analytical interest in a sample. Target isotopes may be implanted in an implant area on a high-purity substrate to pre-concentrate the target isotopes free of contaminants. A known quantity of a tracer isotope may also be implanted. Target isotopes and tracer isotopes may be determined in a mass spectrometer. The present invention provides ultrasensitive determination of target isotopes in the sample.
Opening claim text (preview).
What is claimed is: 1. A method for ultrasensitive determination of a target isotope in a sample, the method comprising the steps of: mass-selecting ions of the target isotope in a mass-selective spectrometer introduced from a high-temperature plasma source to isolate the target isotope from sample matrix components and/or contaminants present in the sample; implanting the isolated target isotope onto the surface of a high-purity substrate in an implant area of a selected size to pre-concentrate the target isotope thereon free of sample matrix components and/or contaminants; implanting a known quantity of a tracer isotope in the implant area on the substrate to obtain a ratio of the target isotope and the tracer isotope in the solid state that defines an isotope dilution standard thereon; ablating the implant area containing the target isotope and the tracer isotope; and determining the concentration of the target isotope at a detection limit of at least about 10 8 atoms per cm 2 or lower. 2. The method of claim 1 , wherein determining the concentration of the target isotope includes a detection limit of at least about 10 7 atoms per cm 2 (2 ppt) or lower. 3. The method of claim 1 , wherein determining the concentration of the target isotope includes determining the isotope dilution ratio based on the ion detector response of both the tracer isotope and the target isotope. 4. The method of claim 1 , wherein the method alternatively includes implanting the target isotope on a high-purity substrate comprising the selected tracer isotope to form an isotope dilution standard in the solid phase on the surface of the substrate. 5. The method of claim 1 , further including ionizing a sample containing the target isotope in a high-temperature plasma source prior to implanting the target isotope. 6. The method of claim 1 , wherein the high-purity substrate replaces a mass detector in the mass-selective spectrometer. 7. The method of claim 1 , wherein the tracer isotope is implanted in the implant area on the surface of the substrate before or after the target isotope of interest. 8. The method of claim 1 , wherein the tracer isotope is either a surrogate isotope of a different element having a mass identical to or adjacent to that of the target isotope, or a different isotope of the same element as the target isotope. 9. The method of claim 1 , wherein the implant area on the surface of the high-purity substrate includes a size of less than or equal to about 1 mm. 10. The method of claim 1 , wherein the target isotope is pre-concentrated on the surface of the substrate by a factor of at least about 10 times or greater. 11. The method of claim 1 , wherein ablation of the implant area containing the pre-concentrated target isotope and the tracer isotope is performed in a time of less than or equal to about 30 seconds on average; or a time of less than or equal to about 10 seconds on average. 12. The method of claim 1 , wherein implantation of the tracer isotope is performed in the same mass spectrometer that determines the concentration of the target isotope. 13. The method of claim 1 , wherein the implantation of the tracer isotope is performed in a mass spectrometer different from the mass spectrometer that determines the concentration of the target isotope. 14. A substrate, comprising: a target isotope from an ionized sample and a known quantity of a tracer isotope implanted from a high temperature plasma plume in an implant area of a selected size that form an isotope dilution standard in the solid phase on the surface of the substrate substantially free of bulk sample matrix components and/or solution contaminants, the implant area containing the implanted isotopes upon analysis in a mass spectrometer determines the concentration of the target isotope at a detection limit of at least about 10 8 atoms per cm 2 or lower. 15. The substrate of claim 14 , wherein the detection limit for the target isotope is at least about 10 7 atoms per cm 2 or lower. 16. The substrate of claim 14 , wherein the determination of the implant area the determination of the concentration of the target isotope in the sample at a detection limit of at least about 10 7 atoms per cm 2 (2 ppt) or lower. 17. The substrate of claim 14 , wherein the tracer isotope is either a surrogate isotope of a different element having a mass identical to or adjacent to that of the target isotope, or a different isotope of the same element as the target isotope. 18. The substrate of claim 14 , wherein the target isotope is pre-concentrated in the implant area on the surface of the substrate by a factor of about 10 times or greater. 19. The substrate of claim 14 , wherein the implant area on the surface of the substrate includes an area less than or equal to about 1 mm 2 on average.
Arrangements for introducing or extracting samples to be analysed, e.g. vacuum locks; Arrangements for external adjustment of electron- or ion-optical components · CPC title
Sample treatment involving radiation, e.g. heat · CPC title
Electron or ion-optical arrangements for separating electrons or ions according to their energy {or mass}(particle separator tubes H01J49/00) · CPC title
by adsorption or absorption · CPC title
mixing the sample with a tracer · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.